Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells

Clinical Cancer Research

Volumn 9, Issue 10 I, 2003, Pages 3794-3800

  Kraemer, Kai ^a   Fuessel, Susanne ^a   Schmidt, Uta ^a   Kotzsch, Matthias ^a   Schwenzer, Bernd ^a   Wirth, Manfred P ^a   Meye, Axel ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TELOMERE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN STRUCTURE, SECONDARY; RNA, MESSENGER; TELOMERASE; TIME FACTORS; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 0141791288     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. Creation of human tumour cells with defined genetic elements. Nature (Lond.), 400: 464-468, 1999.
2. Poole, J. C., Andrews, L. G., and Tollefsbol, T. O. Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene, 269: 1-12, 2001.
3. Dhaene, K., Van Marck, E., and Parwaresch, R. Telomeres, telomerase and cancer: an up-date. Virchows Arch., 437: 1-16, 2000.
4. Orlando, C., Gelmini, S., Selli, C., and Pazzagli, M. Telomerase in urological malignancy. J. Urol., 166: 666-673, 2001.
5. Ito, H., Kyo, S., Kanaya, T., Takakura, M., Inoue, M., and Namiki, M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin. Cancer Res., 4: 1603-1608, 1998.
6. Counter, C. M., Meyerson, M., Eaton, E. N., Ellisen, L. W., Caddle, S. D., Haber, D. A., and Weinberg, R. A. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oneogene, 16: 1217-1222, 1998.
7. Lingner, J., and Cech, T. R. Telomerase and chromosome end maintenance. Curr. Opin. Genet. Dev., 8: 226-2321 1998.
8. Zhu, J., Wang, H., Bishop, J. M., and Blackburn, E. H. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc. Natl. Acad. Sci. USA, 96: 3723-3728, 1999.
9. Chan, S. W., and Blackburn, E. H. New ways not to make ends meet: telomerase, DNA damage proteins and heterochromatin. Oncogene, 21: 553-563, 2002.
10. White, L. K., Wright, W. E., and Shay, J. W. Telomerase inhibitors. Trends Biotechnol., 19: 114-120, 2001.
11. Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H., Meyerson, M., and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nat. Med., 5: 1164-1170, 1999.
12. Herbert, B., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., and Corey, D. R. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Natl. Acad. Sci. USA, 96: 14276-14281, 1999.
13. Schindler, A., Fiedler, U., Meye, A., Schmidt, U., Fussel, S., Pilarsky, C., Herrmann, J., and Wirth, M. P. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int. J. Oncol., 19: 25-30, 2001.
14. Damm, K., Hemmann, U., Garin-Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., Lauritsch, I., Muller, E., Pascolo, E., Sauter, G., Pantic, M., Martens, U. M., Wenz, C., Lingner, J., Kraut, N., Rettig, W. J., and Schnapp, A. A. highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J., 20: 6958-6968, 2001.
15. Kondo, Y., Koga, S., Komata, T., and Kondo, S. Treatment of prostate cancer in vitro and in vivo with 2-5A-anti- telomerase RNA component. Oncogene, 19: 2205-2211, 2000.
16. Koga, S., Kondo, Y., Komata, T., and Kondo, S. Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther., 8: 654-658, 2001.
17. Saretzki, G., Ludwig, A., von Zglinicki, T., and Runnebaum, I. B. Ribozyme-mediated telomerase inhibition induces immediate cell loss but not telomere shortening in ovarian cancer cells. Cancer Gene Ther., 8: 827-834, 2001.
18. Cao, Y. Li, H. Deb, S., and Liu, J. P. TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene, 21: 3130-3139, 2002.
19. Blackburn, E. H. Telomere states and cell fates. Nature (Lond.), 408: 53-56, 2000.
20. Beattie, T. L., Zhou, W., Robinson, M. O., and Harrington, L. Reconstitution of human telomerase activity in vitro. Curr. Biol., 8: 177-180, 1998.
21. Chang, J. T., Chen, Y. L., Yang, H. T., Chen, C. Y., and Cheng, A. J. Differential regulation of telomerase activity by six telomerase subunits. Eur. J. Biochem., 269: 3442-3450, 2002.
22. Tamm, I., Dorken, B., and Hartmann, G. Antisense therapy in oncology: new hope for an old idea? Lancet, 358: 489-497, 2001.
23. Crooke, S. T. Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta, 1489: 31-44, 1999.
24. Vickers, T. A., Wyatt, J. R., and Freier, S. M. Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res., 28: 1340-1347, 2000.
25. Scherr, M., Rossi, J. J., Sczakiel, G., and Patzel, V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res., 28: 2455-2461, 2000.
26. Herbert, B. S., Wright, A. C., Passons, C. M., Wright, W. E., Ali, I. U., Kopelovich, L., and Shay, J. W. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J. Natl. Cancer Inst. (Bethesda), 93: 39-45, 2001.
27. Naka, K., Yokozaki, H., Yasui, W., Tahara, H., and Tahara, E. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines. Biochem. Biophys. Res. Commun., 255: 753-758, 1999.
28. Yokoyama, Y., Takahashi, Y., Shinohara, A., Lian, Z., Wan, X., Niwa, K., and Tamaya, T. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res., 58: 5406-5410, 1998.
29. Yokoyama, Y., Takahashi, Y., Shinohara, A., Wan, X., Takahashi, S., Niwa, K., and Tamayai, T. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem. Biophys. Res. Commun., 273: 316-321, 2000.
30. Zhang, Y., and He, D. M. Effect of Antisense hTERT mRNA oligodeoxynucleotide on telomerase activity of leukemic cells. Cell Biol. Int., 26: 427-431, 2002.
31. Patzel, V., Steidl, U., Kronenwett, R., Haas, R., and Sczakiel, G. A. theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability. Nucleic Acids Res., 27: 4328-4334, 1999.
32. Mathews, D. H., Sabina, J., Zuker, M., and Turner, D. H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol., 288: 911-940, 1999.
33. Fujiyama, C., Jones, A., Fuggle, S., Bicknell, R., Cranston, D., and Harris, A. L. Human bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasion. Br. J. Cancer, 84: 558-564, 2001.
34. Chen, J., Wu, W., Tahir, S. K., Kroeger, P. E., Rosenberg, S. H., Cowsert, L. M., Bennett, F., Krajewski, S., Krajewska, M., Welsh, K., Reed, J. C., and Ng, S. C. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia, 2: 235-241, 2000.
35. Meye, A., Wurl, P., Bache, M., Bartel, F., Grunhaum, U., Mansaard, J., Schmidt, H., and Taubert, H. Colony formation of soft tissue sarcoma cells is inhibited by lipid-mediated antisense oligodeoxynucleotides targeting the human mdm2 oncogene. Cancer Lett., 149: 181-188, 2000.
36. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 25: 3389-3402, 1997.
37. Gunes, C., Lichtsteiner, S., Vasserot, A. P., and Englert, C. Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res., 60: 2116-2121, 2000.
38. Ducrest, A. L. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res., 61: 7594-7602, 2001.
39. Zhang, X., Mar, V., Zhou, W., Harrington, L., and Robinson, M. O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev., 13: 2388-2399, 1999.
40. Kanaya, T., Kyo, S., Hamada, M., Takakura, K., Kitagawa, Y., Harada, H., and Inoue, M. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin. Cancer Res., 6: 1239-1247, 2000.
41. Ferlay, J., Bray, S., Pisani, P., and Parkin, D. M. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5. Lyon, France: IARC Press, 2001.
42. Zhang, Y., and He, D. M. Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia. Hematol. J., 3: 201-205, 2002.